“The benefits of the vaccine outweigh the risks”: EMA commented on the situation with AstraZeneca

Earlier, a number of EU countries, including Germany, France, Italy and Spain, decided to stop using the drug due to alarming news that it can cause thrombosis.

The head of the EMA said that the situation with the Oxford vaccines for the AstraZeneca coronavirus is not a surprise.

The EMA also stressed that “there is no evidence that the vaccine caused blood clots” and that “the number of cases (thrombosis) is not higher than in the normal population”.

“We evaluate all incidents on an individual basis. It is expected that the experts will make a conclusion on Thursday”, – said the head of the EMA.

Prior to that, after a number of countries refused the vaccine, the European Commission nevertheless concluded that “the decisions of the EU member states to suspend the use of the drug are justified,” and noted that there are “more serious problems with the AstraZeneca vaccine”. Now the EMA rhetoric, for some reason, has softened.